TP53 and small cell lung carcinoma: In contrast to NSCLC, identifying therapeutic targets in SCLC has been challenging, partly because driver mutations are primarily loss of function, involving the tumor suppressor genes RB1 and TP53 (4, 5) or currently untargetable (e.g., amplification of MYC family members).